The tumor-associated vasculature imposes major structural and biochemical barriers to the
infiltration of effector T cells and effective tumor control. Correlations between stimulator of …

The stimulator of IFN genes (STING) signaling pathway is a critical link between innate and
adaptive immunity and induces antitumor immune responses. STING is expressed in …

The clinical utility of stimulator of interferon genes (STING) agonists has been limited due to
poor tumour-targeting and unwanted toxicity following systemic delivery. Here we describe a …

The cGAS-STING signaling pathway has emerged as a critical mediator of innate immune
responses, playing a crucial role in improving antitumor immunity through immune effector …

Activation of the stimulator of interferon gene (STING) pathway within the tumor
microenvironment has been shown to generate a strong antitumor response. Although local …

Activation of the stimulator of interferon genes (STING) pathway promotes antitumor
immunity but STING agonists have yet to achieve clinical success. Increased understanding …

Therapeutic cancer vaccines require adjuvants leading to robust type I interferon and
proinflammatory cytokine responses in the tumor microenvironment to induce an anti-tumor …

Insufficient activation of the stimulator of interferon genes (STING) signaling pathway and
profoundly immunosuppressive microenvironment largely limits the effect of cancer …

Cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) are a promising
class of immunotherapeutics that activate innate immunity to increase tumour …

Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …